Halozyme Therapeutics, Inc. (HALO) stock
HALONasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 13/3035% above fair value
$93.04−2.76 (-2.88%)
Close on Nov 19, 2026Market cap $10.56BP/E 27.4Yield –
Halozyme Therapeutics operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Halozyme Therapeutics's operating income for the twelve months ending Jun 30, 2026 was $597.20M, down 12.5% year over year. For fiscal 2025 it was $469.01M, down 15.0% from the year before. The highest annual figure on record is $551.48M in fiscal 2024.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $469.01M | -15.0% |
| FY2024 | Dec 31, 2024 | $551.48M | +63.4% |
| FY2023 | Dec 31, 2023 | $337.57M | +26.2% |
| FY2022 | Dec 31, 2022 | $267.53M | -3.0% |
| FY2021 | Dec 31, 2021 | $275.90M | +91.3% |
| FY2020 | Dec 31, 2020 | $144.26M | – |
| FY2019 | Dec 31, 2019 | -$67.61M | – |
| FY2018 | Dec 31, 2018 | -$69.33M | -185.6% |
| FY2017 | Dec 31, 2017 | $81.00M | – |
| FY2016 | Dec 31, 2016 | -$83.21M | – |
| FY2015 | Dec 31, 2015 | -$27.45M | – |
| FY2014 | Dec 31, 2014 | -$63.04M | – |
| FY2013 | Dec 31, 2013 | -$80.43M | – |
| FY2012 | Dec 31, 2012 | -$53.63M | – |
| FY2011 | Dec 31, 2011 | -$19.84M | – |
| FY2010 | Dec 31, 2010 | -$54.26M | – |
| FY2009 | Dec 31, 2009 | -$58.46M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $287.65M | +42.1% |
| Q1 FY2026 | Mar 31, 2026 | $184.52M | +30.4% |
| Q4 FY2025 | Dec 31, 2025 | -$92.89M | -152.9% |
| Q3 FY2025 | Sep 30, 2025 | $217.92M | +33.5% |
| Q2 FY2025 | Jun 30, 2025 | $202.44M | +72.7% |
| Q1 FY2025 | Mar 31, 2025 | $141.54M | +48.1% |
| Q4 FY2024 | Dec 31, 2024 | $175.50M | +73.7% |
| Q3 FY2024 | Sep 30, 2024 | $163.20M | +84.9% |
| Q2 FY2024 | Jun 30, 2024 | $117.24M | +24.1% |
| Q1 FY2024 | Mar 31, 2024 | $95.54M | +77.6% |
| Q4 FY2023 | Dec 31, 2023 | $101.04M | +35.6% |
| Q3 FY2023 | Sep 30, 2023 | $88.28M | +6.0% |
| Q2 FY2023 | Jun 30, 2023 | $94.46M | +177.3% |
| Q1 FY2023 | Mar 31, 2023 | $53.80M | -28.9% |
| Q4 FY2022 | Dec 31, 2022 | $74.51M | +31.8% |
| Q3 FY2022 | Sep 30, 2022 | $83.29M | +10.2% |
| Q2 FY2022 | Jun 30, 2022 | $34.06M | -63.4% |
| Q1 FY2022 | Mar 31, 2022 | $75.67M | +49.1% |
| Q4 FY2021 | Dec 31, 2021 | $56.53M | -27.2% |
| Q3 FY2021 | Sep 30, 2021 | $75.59M | +87.6% |
| Q2 FY2021 | Jun 30, 2021 | $93.05M | +214.8% |
| Q1 FY2021 | Mar 31, 2021 | $50.74M | – |
| Q4 FY2020 | Dec 31, 2020 | $77.62M | – |
| Q3 FY2020 | Sep 30, 2020 | $40.30M | – |
| Q2 FY2020 | Jun 30, 2020 | $29.56M | – |
| Q1 FY2020 | Mar 31, 2020 | -$3.22M | -208.7% |
| Q4 FY2019 | Dec 31, 2019 | -$32.06M | – |
| Q3 FY2019 | Sep 30, 2019 | -$24.54M | – |
| Q2 FY2019 | Jun 30, 2019 | -$13.98M | – |
| Q1 FY2019 | Mar 31, 2019 | $2.97M | – |
| Q4 FY2018 | Dec 31, 2018 | -$71.00K | -100.1% |
| Q3 FY2018 | Sep 30, 2018 | -$25.47M | -415.4% |
| Q2 FY2018 | Jun 30, 2018 | -$20.07M | – |
| Q1 FY2018 | Mar 31, 2018 | -$23.71M | – |
| Q4 FY2017 | Dec 31, 2017 | $125.93M | – |
| Q3 FY2017 | Sep 30, 2017 | $8.08M | – |
| Q2 FY2017 | Jun 30, 2017 | -$25.48M | – |
| Q1 FY2017 | Mar 31, 2017 | -$27.53M | – |
| Q4 FY2016 | Dec 31, 2016 | -$22.58M | – |
| Q3 FY2016 | Sep 30, 2016 | -$22.74M | – |
See a number that looks wrong?